MedTrace Logo

Use of GM-CSF Treatment in Recurrent Implantation Failure

NCT01715974 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2022-07-20

No results posted yet for this study

Summary

The purpose of this study is to determine whether in Assisted Reproductive Technologies the treatment with GM-CSF, a growth factor working on stem cells, may improve the pregnancy rate and pregnancy outcome in patients experiencing recurrent implantation failure in IVF cycles.

Conditions

  • Women With Recurrent Implantation Failure in IVF

Interventions

DRUG

GM-CSF group

30 micrograms/day of GM-CSF from the day of embryo transfer through the day of beta HCG test

DRUG

CONTROL

saline infusion every day from the day of embryo transfer through the day of beta HCG test

Sponsors & Collaborators

  • Centre for Endocrinology and Reproductive Medicine, Italy

    lead NETWORK

Principal Investigators

  • Marco Sbracia, MD · Centre for Endocrinology and Reproductive Medicine, Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-12
Primary Completion
2022-07-31
Completion
2022-08-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01715974 on ClinicalTrials.gov